Method of isolating 1-N.sup.2 -((S)-ethoxycarbonyl)-3-phenylpropyl)-N.sup.6 -trifluoroacetyl!-L-lysyl-L-proline (lisinopril (TFA) ethyl ester, LPE)

US5907044A · kind A · utility

Assignee

• Degussa AG · DE

Inventors

• Matthias Kottenhahn · Alzenau, DE
• Roland Moller · Herbrechtingen, DE
• Michael Kraft · Blaustein, DE
• Karlheinz Drauz · Alzenau, DE
• Klaus Stingl · Alzenau, DE

Key dates

• Filing date: Oct 16, 1997
• Grant date: May 25, 1999
• Expiry date: Oct 16, 2017

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of isolating 1-N.sup.2 -((S)-ethoxycarbonyl)-3-phenylpropyl)-N.sup.6 -trifluoroacetyl!-L-lysyl-L-proline (lisinopril (TFA) ethyl ester, LPE). The solvent or solvent mixture used for the extraction is also a main constituent of the solvent or solvent mixture from which the crystallization takes place. High yield as well as good purity of the end product are obtained, without distillation. 1-N.sup.2 -((S)-ethoxycarbonyl)-3-phenylpropyl)-N.sup.6 -trifluoroacetyl!-L-lysyl-L-proline (lisinopril (TFA) ethyl ester, LPE) is described as a precursor for producing an ACE inhibitor.